ilomastat has been researched along with Brain Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annabi, B; Haidara, K; Pratt, J | 1 |
| Annabi, B; Pratt, J; Roy, R | 1 |
2 other study(ies) available for ilomastat and Brain Neoplasms
| Article | Year |
|---|---|
MT1-MMP Expression Levels and Catalytic Functions Dictate LDL Receptor-Related Protein-1 Ligand Internalization Capacity in U87 Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Ligands; Low Density Lipoprotein Receptor-Related Protein-1; Matrix Metalloproteinase 14; Matrix Metalloproteinase Inhibitors | 2022 |
Concanavalin-A-induced autophagy biomarkers requires membrane type-1 matrix metalloproteinase intracellular signaling in glioblastoma cells.
Topics: Acridine Orange; Autophagy; Brain Neoplasms; Cell Line, Tumor; Concanavalin A; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Indoles; Mannose; Matrix Metalloproteinase 14; Neoplasm Proteins; Protein Structure, Tertiary; RNA, Small Interfering; Signal Transduction; Vacuoles | 2012 |